# Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

> **NCT01259323** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Dermatitis

## Interventions

- **BIOLOGICAL:** REGN668
- **BIOLOGICAL:** REGN668
- **BIOLOGICAL:** REGN668

## Key facts

- **NCT ID:** NCT01259323
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01259323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01259323, "Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01259323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*